References
- Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017 Feb;31(2):205–212.
- Boehncke WH, Schön MP. Psoriasis. Lancet. 2015 Sep 5;386(9997):983–994.
- Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018 Jun 2;391(10136):2273–2284.
- Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013 Feb;133(2):377–385.
- Horn EJ, Fox KM, Patel V, et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol. 2007 Dec;57(6):963–971.
- Rendon A, Schakel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019 Mar 23;20(6):1475.
- Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021 Apr 3;397(10281):1301–1315.
- Arakawa A, Siewert K, Stohr J, et al. Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med. 2015 Dec 14;212(13):2203–2212.
- Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat Genet. 2009 Feb;41(2):199–204.
- Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005 Jul 4;202(1):135–143.
- Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity. 2003 Nov;19(5):641–644.
- Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003 Feb;3(2):133–146.
- Tang L, Yang X, Liang Y, et al. Transcription factor retinoid-related orphan receptor gammat: a promising target for the treatment of psoriasis. Front Immunol. 2018;9:1210.
- Ghoreschi K, Balato A, Enerback C, et al. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021 Feb 20;397(10275):754–766.
- Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011 Mar;131(3):677–687.
- Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016 Jan;12(1):49–62.
- Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol. 2015 Jun;15(6):362–374.
- Brembilla NC, Senra L, Boehncke WH. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol. 2018;9:1682.
- Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009 Jun;129(6):1339–1350.
- Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011 Aug 18;365(7):620–628.
- Calabrese L, Caldarola G, Peris K, et al. Recalcitrant Sweet Syndrome successfully treated with Adalimumab. J Dtsch Dermatol Ges. 2021 Jan;19(1):122–124.
- Morizane S, Yamasaki K, Muhleisen B, et al. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J Invest Dermatol. 2012 Jan;132(1):135–143.
- Chiricozzi A, Romanelli P, Volpe E, et al. Scanning the immunopathogenesis of psoriasis. Int J Mol Sci. 2018 Jan 8;19(1):179.
- Banerjee S, Biehl A, Gadina M, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017 Apr;77(5):521–546.
- Shreberk-Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: a systematic review. J Am Acad Dermatol. 2017 Apr;76(4):745–753 e19.
- Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020 May 19;323(19):1945–1960.
- D’Urso DF, Chiricozzi A, Pirro F, et al. New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis. G Ital Dermatol Venereol. 2020 Aug;155(4):411–420.
- Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005 Mar;64(Suppl2):ii65–8.
- Bruner CR, Feldman SR, Ventrapragada M, et al. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J. 2003 Feb;9(1):2.
- Ben Abdallah H, Johansen C, Iversen L. Key signaling pathways in psoriasis: recent insights from antipsoriatic therapeutics. Psoriasis (Auckl). 2021;11:83–97.
- FDA approval of Remicade (infliximab) for the treatment of psoriasis. Published November 2013 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5359lbl.pdf. Cited 2022 Nov 23
- FDA approval of Humira (Adalimumab) for the treatment of psoriasis. Published December 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125057s417lbl.pdf. Cited 2022 Nov 23
- FDA approval of Cimzia (certolizumab) for the treatment of psoriasis. Published April 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125160s270lbl.pdf. Cited 2022 Nov 23
- FDA approval of Enbrel (etanercept) for the treatment of psoriasis. Published September 2011. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103795s5503lbl.pdf. Cited 2022 Nov 23
- Mitoma H, Horiuchi T, Tsukamoto H, et al. Molecular mechanisms of action of anti-TNF-alpha agents - Comparison among therapeutic TNF-alpha antagonists. Cytokine. 2018 Jan;101:56–63.
- FDA approval of Cosentyx (secukinumab) for the treatment of psoriasis. Published May 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125504s043lbl.pdf. Cited 2022 Nov 23
- FDA approval of Taltz (ixekizumab) for the treatment of psoriasis. Published December 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125521s004lbl.pdf. Cited 2022 Nov 23
- FDA approval of Siliq (brodalumab) for the treatment of psoriasis. Published 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf. Cited 2022 Nov 23
- EMA approval of Bimzelx (bimekizumab) for the treatment of psoriasis. Published August 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf. Cited 2022 Nov 23
- FDA approval of Stelara (ustekinumab) for the treatment of psoriasis. Published September 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761044lbl.pdf. Cited 2022 Nov 24
- FDA approval of Tremfya (guselkumab) for the treatment of psoriasis. Published July 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761061s007lbl.pdf. Cited 2022 Nov 24
- FDA approval of Ilumya (Tildrakizumab) for the treatment of psoriasis. Published March 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf. Cited 2022 Nov 24
- FDA approval of Skyrizi (Risankizumab) for the treatment of psoriasis. Published January 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761105s014lbl.pdf. Cited 2022 Nov 24
- FDA approval of Otezla (Apremilast) for the treatment of psoriasis. Published June 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205437s006lbl.pdf. Cited 2022 Nov 24
- Chiricozzi A, Caposiena D, Garofalo V, et al. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast. Expert Rev Clin Immunol. 2016;12(3):237–249.
- Behrens FTP. Wetzel D OP0258 IZOKIBEP (ABY-035) in patients with active psoriatic arthritis – 16-week results from a phase 2 study. Ann Rheum Dis. 2022;81:170–171.
- Sun S, Ding Z, Yang X, et al. Nanobody: a small antibody with big implications for tumor therapeutic strategy. Int J Nanomedicine. 2021;16:2337–2356.
- Papp KA, Weinberg MA, Morris A, et al. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet. 2021 Apr 24;397(10284):1564–1575.
- Zhang C, Yan K, Diao Q, et al. A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2022 Jul;87(1):95–102.
- Workman CJ, Vignali DA. Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol. 2005 Jan 15;174(2):688–695.
- Okazaki T, Okazaki IM, Wang J, et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med. 2011 Feb 14;208(2):395–407.
- Wierz M, Pierson S, Guyonnet L, et al. Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. Blood. 2018 Apr 5;131(14):1617–1621.
- Workman CJ, Rice DS, Dugger KJ, et al. Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur J Immunol. 2002 Aug;32(8):2255–2263.
- Poirier N, Haudebourg T, Brignone C, et al. Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3(+))-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates. Clin Exp Immunol. 2011 May;164(2):265–274.
- Ellis J, Jbm D, Srinivasan N, et al. Depletion of LAG-3(+) T cells translated to pharmacology and improvement in psoriasis disease activity: a phase I randomized study of mAb GSK2831781. Clin Pharmacol Ther. 2021 May;109(5):1293–1303.
- Curnock AP, Bossi G, Kumaran J, et al. Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors. JCI Insight. 2021 Oct 22;6:20.
- Papp KA, Gooderham M, Jenkins R, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody. Br J Dermatol. 2019 Jun;180(6):1352–1360.
- Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J Am Acad Dermatol. 2022 Jan;86(1):148–157.
- Tehlirian C, Singh RSP, Pradhan V, et al. Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2022 Aug;87(2):333–342.
- Gege C. Retinoic acid-related orphan receptor gamma t (RORgammat) inverse agonists/antagonists for the treatment of inflammatory diseases - where are we presently? Expert Opin Drug Discov. 2021 Dec;16(12):1517–1535.
- Haggerty HG, Sathish JG, Gleason CR, et al. Thymic lymphomas in a 6-month rasH2-Tg mouse carcinogenicity study with the RORgammat inverse agonist, BMS-986251. Toxicol Sci. 2021 Aug 30;183(1):93–104.
- Vitae pharmaceuticals, 8-K - current report, published: 2016-Mar16. [cited 2021 Mar 15]. Available from: https://sec.report/Document/0001104659-16-105501/
- Zampeli E, Tiligada E. The role of histamine H4 receptor in immune and inflammatory disorders. Br J Pharmacol. 2009 May;157(1):24–33.
- Alcain J, Adp IC, Barrientos G, et al. Mechanisms of unconventional CD8 Tc2 lymphocyte induction in allergic contact dermatitis: role of H(3)/H(4) histamine receptors. Front Immunol. 2022;13:999852.
- Han SH, Hur MS, Kim MJ, et al. Preliminary study of histamine H(4) receptor expressed on human CD4(+) T cells and its immunomodulatory potency in the IL-17 pathway of psoriasis. J Dermatol Sci. 2017 Oct;88(1):29–35.
- Taniguchi T, Matsui H, Fujita T, et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature. 1983 Mar 24-30;302(5906):305–310.
- Abbas AK, Trotta E, RS D, et al. Revisiting IL-2: biology and therapeutic prospects. Sci Immunol. 2018 Jul 6;3:25.
- Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther. 2006 Mar;109(3):366–398.
- Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018;9:1048.
- Maurice DH, Ke H, Ahmad F, et al. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014 Apr;13(4):290–314.
- Strober B, Alikhan A, Lockshin B, et al. Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: pharmacodynamic results from the UNVEIL study. J Dermatol Sci. 2019 Dec;96(3):126–133.
- Garcet S, Nograles K, Correa da Rosa J, et al. Synergistic cytokine effects as apremilast response predictors in patients with psoriasis. J Allergy Clin Immunol. 2018 Sep;142(3):1010–1013 e6.
- Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020 Jul 16;383(3):229–239.
- Hennig P, Fenini G, Di Filippo M, et al. Electrophiles against (Skin) diseases: more than Nrf2. Biomolecules. 2020 Feb 11;10:2.
- Kobayashi EH, Suzuki T, Funayama R, et al. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat Commun. 2016 May 23;7:11624.
- Kastrati I, Siklos MI, Calderon-Gierszal EL, et al. Dimethyl fumarate inhibits the nuclear factor kappab pathway in breast cancer cells by covalent modification of p65 protein. J Biol Chem. 2016 Feb 12;291(7):3639–3647.
- EMA approval of Skilarence (dimethyl fumarate) for the treatment of psoriasis. Published June 2017 Skilarence, INN-dimethyl fumarate (europa.eu). Cited 2022 Nov 24.
- Mrowietz U, Kircik L, Reich K, et al. Tepilamide fumarate (PPC-06) extended release tablets in patients with moderate-to-severe plaque psoriasis: safety and efficacy results from the randomized, double-blind, placebo-controlled AFFIRM study. J Clin Aesthet Dermatol. 2022 Jan;15(1):53–58.
- Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German multicentre study. Br J Dermatol. 1998 Mar;138(3):456–460.
- Mrowietz U, Szepietowski JC, Loewe R, et al. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm((R)) - and placebo-controlled trial (BRIDGE). Br J Dermatol. 2017 Mar;176(3):615–623.
- Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003 Jun;4(6):446–456.
- Biswas PS, Gupta S, Chang E, et al. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J Clin Invest. 2010 Sep;120(9):3280–3295.
- Weiss JM, Chen W, Nyuydzefe MS, et al. ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings. Sci Signal. 2016 Jul 19;9(437):ra73.
- Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814–16819.
- Zanin-Zhorov A, Weiss JM, Trzeciak A, et al. Cutting edge: selective oral ROCK2 inhibitor reduces clinical scores in patients with psoriasis vulgaris and normalizes skin pathology via concurrent regulation of IL-17 and IL-10. J Immunol. 2017 May 15;198(10):3809–3814.
- Edwards MJ, Marks R, Dykes PJ, et al. Heat shock proteins in cultured human keratinocytes and fibroblasts. J Invest Dermatol. 1991 Mar;96(3):392–396.
- Tukaj S, Zillikens D, Kasperkiewicz M. Inhibitory effects of heat shock protein 90 blockade on proinflammatory human Th1 and Th17 cell subpopulations. J Inflamm (Lond). 2014 Apr 2;11(1):10.
- Kumar P, Kolls JK. Act1-hsp90 heats up TH17 inflammation. Nat Immunol. 2013 Jan;14(1):16–17.
- Prinsloo E, Kramer AH, Edkins AL, et al. STAT3 interacts directly with Hsp90. IUBMB Life. 2012 Mar;64(3):266–273.
- Kakeda M, Arock M, Schlapbach C, et al. Increased expression of heat shock protein 90 in keratinocytes and mast cells in patients with psoriasis. J Am Acad Dermatol. 2014 Apr;70(4):683–690 e1.
- Zhou Z, Li X, Qian Y, et al. Heat shock protein 90 inhibitors suppress pyroptosis in THP-1 cells. Biochem J. 2020 Oct 30;477(20):3923–3934.
- Carlstrom M, Ekman AK, Petersson S, et al. Genetic support for the role of the NLRP3 inflammasome in psoriasis susceptibility. Exp Dermatol. 2012 Dec;21(12):932–937.
- Hansen RS, Thuesen KKH, Bregnhoj A, et al. The HSP90 inhibitor RGRN-305 exhibits strong immunomodulatory effects in human keratinocytes. Exp Dermatol. 2021 Jun;30(6):773–781.
- Stenderup K, Rosada C, Gavillet B, et al. Debio 0932, a new oral Hsp90 inhibitor, alleviates psoriasis in a xenograft transplantation model. Acta Derm Venereol. 2014 Nov;94(6):672–676.
- Bregnhoj A, Thuesen KKH, Emmanuel T, et al. HSP90 inhibitor RGRN-305 for oral treatment of plaque-type psoriasis: efficacy, safety and biomarker results in an open-label proof-of-concept study. Br J Dermatol. 2022 May;186(5):861–874.
- Evelo biosciences presents late-breaking oral abstract on data from phase 2 trial of EDP1815 in psoriasis at 2022 American Academy of Dermatology annual meeting. Evelo Biosciences. Press release. Published March 26, 2022. Available from: https://ir.evelobio.com/news-releases/news-release-details/evelo-biosciences-presents-late-breaking-oral-abstract-data/. Cited 2022 Dec 3.
- Siegel SAR, Winthrop KL. In the real world: infections associated with biologic and small molecule therapies in psoriatic arthritis and psoriasis. Curr Rheumatol Rep. 2019 Jun 6;21(7):36.
- Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. 2014 Feb;170(2):261–273.
- Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018 Apr;77(4):523–532.
- Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. J Inflamm Res. 2020;13:519–531.